Clinical Trial Update: First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the ORM regimen (Orelabrutinib, Rituximab, and Methotrexate) as first-line therapy for primary central nervous system lymphoma has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• METHOTREXATE (METHOTREXATE)
• Orelabrutinib (orelabrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Ningbo No. 1 Hospital | Conditions: Primary Central Nervous System Lymphoma | Phase 2 | Status: COMPLETED